Delivery Order SPE2DR25D2206-SPE2DR26F9CV5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,139.92 to AmerisourceBergen Drug Corp for the supply of Bromfenac Sodium 0.09% eye drops (1.7mL units). This firm fixed-price delivery order, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The award was made through open competition with no set-aside designation....
- The Defense Logistics Agency awarded a $2,638.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Bromfenac Sodium 0.09% eye drops in 1.7 mL quantities, with an ultimate completion date of February 5, 2026. This non-set-aside contract was competitively awarded and will be performed at the awardee's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc. (doing business as AmerisourceBergen), a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,328.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Bromfenac Sodium 0.09% eye drops (1.7 mL) on June 5, 2025, with an ultimate completion date of June 6, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement from the vendor's place of performance in Conshohocken, Pennsylvania. The award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Bromfenac Sodium 0.09% eye drops. This $1,488.72 contract has a performance period through March 21, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Bromfenac Sodium 0.09% eye drops (1.7 mL) with a ceiling value of $7,904.95. This firm fixed-price delivery order is non-competitive and represents a single pharmaceutical product delivery to support federal medical supply needs. The contract is set to reach ultimate completion by August 13, 2025, with performance conducted from the contractor's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of Bromfenac Sodium 0.09% eye drops in 1.7mL units, with a contract ceiling value of $9,699.75. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of May 21, 2025. The delivery order is a child contract issued under AmerisourceBergen's...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Bromfenac Sodium 0.09% eye drops in 1.7 mL vials. The contract has a firm fixed price, with a ceiling value of $1,457.11, and a performance period that runs through July 1, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp...
- This federal contract award to Amerisourcebergen Drug Corp (AmerisourceBergen), a major pharmaceutical distributor, is for the delivery of Bromfenac Sodium 0.09% Eye Drops 1.7ML. The $1,575.92 Firm Fixed Price Delivery Order was awarded by the Defense Logistics Agency (DLA), a defense agency, with an ultimate completion date of September 5, 2024. The contract is not designated as a set-aside award. AmerisourceBergen, a for-profit organization, holds a significant $999,999,999 Indefinite Delivery...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a global pharmaceutical sourcing and distribution company. The award is for the provision of Bromfenac Sodium 0.09% Eye Drops in 1.7ml containers, with a total ceiling value of $1,131.37 and a period of performance through March 12, 2024. The award is part of a larger indefinite delivery contract (IDC) valued at up to...
- This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,276.29, is for the delivery of Bromfenac Sodium 0.07% Eye Drops in 3 mL containers. The contract is a Firm Fixed Price Delivery Order with a completion date of February 13, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9CV5Delivery Order
The Defense Logistics Agency awarded a $7,789.68 delivery order to AmerisourceBergen Drug Corp for Bromfenac Sodium 0.09% eye drops (1.7mL) under a firm fixed-price contract. The award was made on November 24, 2025, with an ultimate completion date of November 25, 2025, and represents a non-competitive set-aside delivery against AmerisourceBergen's existing contract vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support, enabling AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. The company's competitive positioning within the DLA's evolving Pharmaceutical Prime Vendor Global Program reflects its capability to fulfill diverse federal medical supply requirements across multiple geographic regions and customer bases, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 11/23/25 |